Copyright
©The Author(s) 2017.
World J Gastroenterol. Sep 28, 2017; 23(36): 6549-6570
Published online Sep 28, 2017. doi: 10.3748/wjg.v23.i36.6549
Published online Sep 28, 2017. doi: 10.3748/wjg.v23.i36.6549
Table 1 Treatment options for alcoholic liver disease and alcoholic steatohepatitis
General management |
Abstinence |
Nutritional support |
Glucocorticosteroids |
Pentoxifylline |
Anti-TNF therapy |
Antioxidants |
Liver transplantation |
Potential new therapies |
Probiotics and antibiotics |
S-adenosylmethionine |
Betaine |
Targeting various chemokines and interleukins |
Endocannabinoids antagonists |
Osteopontin inhibition |
Stem cell therapy |
Table 2 Treatment options for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Lifestyle changes | Weight loss |
Dietary changes | |
Exercise | |
Insulin sensitizers | Thiazolidinedione’s |
Metformin | |
Lipid lowering agents | Statins |
Ezetimibe | |
Hepatoprotective agents | UDCA |
Antioxidants | Vitamin E |
Incretin analogues | GLP-1 agonists |
DPP-IV inhibitors | |
Anti-inflammatory agents | PTX |
Others | Probiotics |
Angiotensin receptor blockers | |
Endocannabinoid antagonists | |
Bariatric surgery | |
Liver transplantation | |
Potential new therapeutic options | Caspases inhibitors |
ASK1 inhibitors | |
p38 MAPK inhibitors | |
PPAR- alpha and delta agonists | |
FXR agonists | |
NOX-1/4 inhibitors | |
Galectin-3 antagonists | |
Acetyl CoA carboxylase inhibitors | |
FGF-21 and FGF-19 analogues | |
CCR2 and CCR5 inhibitors | |
SCD-1 inhibitors | |
Lysyl oxidase-like 2 inhibitors | |
Sirtuins |
- Citation: Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol 2017; 23(36): 6549-6570
- URL: https://www.wjgnet.com/1007-9327/full/v23/i36/6549.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i36.6549